NFE2L2 and diabetes mellitus: It should be mentioned that Nrf2 upregulation has also been observed for non-cancerous treatment applications when the drug is revealed to be toxic, such as treatment with bardoxolone methyl in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease [232].